Home Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.8, p.582–589,2021

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.2

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.122, No.8, p.582–589,2021

Title: Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-1
Author: S. Gormez, H. K. Gumusel, E. Ekicibasi, A. Degirmencioglu, A. Paudel, G. Akan, F. Atalar, R. Erdim, E. Eroglu, S. Dagdelen, N. Sariguzel, C. E. Kirisoglu, B. Pamukcu

Abstract: OBJECTIVES: Low molecular weight heparin (LMWH) may provide beneficial effects on outcomes of COVID-19. We aimed to examine the impact of LMWH treatment on clinical outcomes (duration of hospitalization, admission to intensive care unit, the requirement for mechanical ventilation, and death) of COVID-19 patients with normal D-dimer levels at admission.
BACKGROUND: Coronavirus disease-2019 (COVID-19) predisposes patients to arterial and venous thrombosis.

METHODS: In this retrospective, multicentre and observational study we analysed the data of 308 confirmed COVID-19 patients with normal D-dimer levels at initial admission. After propensity score matching (PSM) patients were grouped; Group 1; patients who received LMWH with D-dimer ≤0.5 mg/L, Group 2; patients who received LMWH after D-dimer levels exceeded 0.5 mg/L, and Group 3; patients who did not receive LMWH.
RESULTS: After PSM, each group comprised 40 patients. The patients in Group1 had the best clinical outcomes compared to the other groups. Group 3 had the worst clinical outcomes (p<0.005). The benefit of LMWH increased with early prophylactic therapy especially when started while the D-dimer levels were ≤0.5 mg/L.
CONCLUSION: Our results strongly suggest that proactive LMWH therapy improves clinical outcomes in hospitalized COVID-19 patients even with normal D-dimer levels (≤ 0.5 mg/L) (Tab. 3, Fig. 2, Ref. 34).

Keywords: COVID-19; SARS-CoV-2; thrombosis; antithrombotic therapy; low-molecular-weight heparin; D-dimer; enoxaparin
Published online: 20-Jul-2021
Year: 2021, Volume: 122, Issue: 8 Page From: 582, Page To: 589
doi:10.4149/BLL_2021_093


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.